资产概览：沃什交易逆转美元与黄金走势 [Table_Authors] 方奕(分析师) ——资产配置全球跟踪 2026 年 2 月第 1 期 本报告导读： 01/26-01/30，沃什获提名概率飙升引发市场短期"沃什交易"，呈现"美元涨+黄金跌 +长端美债跌"的资产格局。原油领涨。韩国 KS11 与 KOSDAQ 年内涨幅破 20%。 略 投资要点： 策略研究 /[Table_Date] 2026.02.01 | | 021-38031658 | | --- | --- | | | fangyi2@gtht.com | | 登记编号 | S0880520120005 | | | 郭佼佼(分析师) | | | 021-38031042 | | | guojiaojiao2@gtht.com | | 登记编号 | S0880523070002 | [Table_Report] 相关报告 成交活跃度上升，上证 50 估值领涨 2026.02.01 2025A 业绩预告情况跟踪（2026.01.28） 2026.01.29 ETF 资金大幅流出，主动外资流入边际抬升 2026.01.27 资产概览：国际金银价格刷新历史 ...

Investment Rating - The report rates the military industry as "Overweight" [4] Core Insights - The military sector is expected to have a long-term positive trend, supported by the 20th National Congress of the Communist Party of China, which emphasizes achieving the centenary goal of building a strong military and modernizing national defense [7][8] - The military industry index fell by 7.60% from January 26 to January 31, underperforming the broader market by 7.16 percentage points, ranking 29th out of 29 sectors [12][13] - The training program for the Fujian aircraft carrier is progressing smoothly, with expectations that it will be capable of entering the Pacific for long-range training by 2026 [8][9] Summary by Sections Investment Highlights - The military industry is experiencing a downturn, but the Fujian aircraft carrier's training plan is advancing as scheduled [8] - The report highlights several companies for investment, including: 1. Assembly: AVIC Shenyang Aircraft, AVIC Xi'an Aircraft, Aero Engine Corporation of China, and High-Tech Infrared 2. Components: AVIC Optoelectronics, Zhimin Technology, Shaanxi Huada, Ruichuang Micro-Nano, and Unisplendour 3. Subsystems: Aerospace Electronics, Guorui Technology, Guobo Electronics, AVIC Avionics, North Navigation, and Aerospace Nanhu 4. Materials and Processing: Jiachitech, AVIC High-Tech, Western Materials, Aviation Materials, Hanya Technology, Guangwei Composite, Filihua, Huayin Technology, and Plit [9][10] Market Review - The military industry index underperformed the market, with a decline of 7.60% compared to a 0.44% drop in the Shanghai Composite Index and a 0.09% drop in the ChiNext Index [12][13] - The best-performing index was the China Securities National Security Index, which fell by 6.21% [14] - The defense information technology sector showed better performance, with notable gains from stocks like *ST Chengchang (+15.48%) and Western Materials (+13.02%) [16][21] Major News in the Military Industry - International tensions are escalating, with the U.S. increasing military presence in the Middle East amid rising tensions with Iran and threats from Houthi forces [25][26] - The Russian military has conducted airstrikes on Ukrainian energy infrastructure, resulting in injuries and power outages across multiple regions [26] - The report notes that the Fujian aircraft carrier is on track to achieve operational capabilities by 2026, which is seen as a positive development for China's naval capabilities [28]

股票研究 /[Table_Date] 2026.02.02 鹰派扰动，价格巨震 [Table_Industry] 有色金属 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 李鹏飞(分析师) | 010-83939783 | lipengfei2@gtht.com | S0880519080003 | | 魏雨迪(分析师) | 021-38674763 | weiyudi@gtht.com | S0880520010002 | | 刘小华(分析师) | 021-38038434 | liuxiaohua@gtht.com | S0880523120003 | | 王宏玉(分析师) | 021-38038343 | wanghongyu@gtht.com | S0880523060005 | | 梁琳(分析师) | 021-23185845 | lianglin@gtht.com | S0880525070014 | | 李阳(分析师) | 021-23185618 | liyang7@gtht.com | S088052504 ...

Investment Rating - The report rates the military industry as "Overweight" [4] Core Insights - The military sector is expected to have a long-term positive trend, supported by the 20th National Congress of the Communist Party of China, which emphasizes achieving the centenary goal of building a strong military and advancing the modernization of national defense and armed forces [7][8] - The military industry index fell by 7.60% from January 26 to January 31, underperforming the broader market by 7.16 percentage points, ranking 29th out of 29 sectors [12][13] - The training plan for the Fujian aircraft carrier is progressing smoothly, with expectations that it will be capable of entering the Pacific for long-range training by 2026 [8][9] Summary by Sections Market Review - The military sector experienced a decline of 7.60%, significantly underperforming the Shanghai Composite Index, which fell by 0.44% [12][13] - The China Securities National Security Index performed the best among military indices, with a decline of 6.21%, ranking 1st out of 10 [14][18] - The defense information technology sector showed better performance, with notable gains from stocks like *ST Chengchang (+15.48%) and West Materials (+13.02%) [16][21] Major News in the Military Industry - International tensions are escalating, with the U.S. increasing military presence in the Middle East amid rising tensions with Iran, and the Houthis threatening shipping in the Red Sea [25][26] - The Russian military conducted airstrikes on Ukrainian energy infrastructure, resulting in injuries and power outages across multiple regions [26] - The Chinese Ministry of Defense confirmed the successful training progress of the Fujian aircraft carrier, which is expected to enhance its operational capabilities by 2026 [28][30] Investment Recommendations - Recommended stocks include: 1. Assembly: AVIC Shenyang Aircraft, AVIC Xi'an Aircraft, Aero Engine Corporation of China, and High-Def Infrared 2. Components: AVIC Optoelectronics, Zhimin Technology, Shaanxi Huada, Ruichuang Micro-Nano, and Unisoc 3. Subsystems: Aerospace Electronics, Guorui Technology, Guobo Electronics, AVIC Onboard, Northern Navigation, and Aerospace Nanhu 4. Materials and Processing: Jiachitech, AVIC High-Tech, Western Materials, Aviation Materials, and Huayin Technology [9][10]

Investment Rating - The report maintains a "Buy" rating for the company [5][2] - The target price is set at 29.03 CNY per share [5][2] Core Insights - The company is expected to see a recovery in revenue and profit in 2026, despite short-term performance pressures [2][11] - The decline in profit for Q4 2025 has narrowed, indicating potential stabilization [11] - The company anticipates a significant drop in net profit for 2025, with estimates ranging from 308 million to 320 million CNY, reflecting a year-on-year decline of 62.33% to 64.68% [11] Financial Summary - Total revenue for 2023 is reported at 6,806 million CNY, with a slight decline of 1.1% [4] - Net profit attributable to shareholders for 2023 is 803 million CNY, down 17.8% [4] - Earnings per share (EPS) for 2023 is 1.59 CNY [4] - The company expects a recovery in net profit to 653 million CNY in 2026, representing a growth of 112.1% compared to 2025 [4] - The projected net profit for 2027 is 785 million CNY, showing a further increase of 20.3% [4] Market Data - The company's market capitalization is 11,574 million CNY [6] - The stock has traded within a range of 20.96 to 27.82 CNY over the past 52 weeks [6] - The current price is 22.88 CNY, indicating potential upside to the target price [5][6] Valuation Metrics - The price-to-earnings (P/E) ratio for 2026 is projected at 17.73 [4] - The price-to-book (P/B) ratio at the current price is 2.2 [7] - The return on equity (ROE) is expected to be 11.1% in 2026 [4]

Investment Rating - The industry investment rating is "Overweight" [5][16]. Core Insights - The average weekly price of liquid oxygen and nitrogen has slightly increased, while the price of liquid argon continues its significant year-on-year upward trend. Rare gases are experiencing low-level fluctuations [2][5]. - Hangyang Group has won a bid for a nitrogen production equipment project at a refinery in West Africa, which is the largest refining project in the region with an annual crude oil processing capacity of 10 million tons and a total investment of approximately 6 billion USD [2][5]. - The successful trial operation of a high-pressure CO2 compressor by ShanGu CCS marks a significant breakthrough in carbon capture and storage technology in China [2][5]. Price Trends - As of January 29, 2026, the weekly price data for gases is as follows: 1. Liquid Oxygen: Average price is 336 CNY/ton, with a 0.9% increase month-on-month and a 0.6% decrease year-on-year 2. Liquid Nitrogen: Average price is 364 CNY/ton, with a 0.5% increase month-on-month and a 2% increase year-on-year 3. Liquid Argon: Average price is 1104 CNY/ton, with a 3.83% decrease month-on-month and a 144.83% increase year-on-year 4. Rare Gases: High-purity helium gas (cylinder) is 80.21 CNY/cubic meter, with a 5.32% decrease month-on-month and a 17.85% decrease year-on-year [5][6][10]. Company Recommendations - Recommended stocks include Hangyang Co., Ltd. and ShanGu Power, with related stocks being Fostar and Zhongtai Co., Ltd. [5][6].

业绩超预期，重拾强劲动能 新易盛(300502) ——2025 业绩预告点评 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | [Table_Invest] 评级： | 增持 | | --- | --- | --- | --- | --- | --- | | 余伟民(分析师) | 010-50949926 | yuweimin@gtht.com | S0880525040028 | | | | 王彦龙(分析师) | 010-83939775 | wangyanlong@gtht.com | S0880519100003 | [Table_Target] 目标价格： | 508.80 | | 黎明聪(分析师) | 0755-23976500 | limingcong@gtht.com | S0880523080008 | | | | 桂海晟(研究助理) | 021-38031384 | guihaisheng@gtht.com | S0880124070058 | | | | | | | | Table_CurPrice] [当前价格： | 419.49 | 本报告导读： 上调 20 ...

Investment Rating - The report maintains an "Overweight" rating for the steel industry [5]. Core Insights - Demand is expected to gradually stabilize, while supply-side constraints are anticipated to continue, leading to a potential recovery in the steel industry's fundamentals. If supply policies are implemented, the contraction in supply may accelerate, facilitating a quicker industry upturn [3][4]. Summary by Sections Steel Market Overview - Steel prices have decreased, with the Shanghai rebar price dropping by 20 CNY/ton to 3240 CNY/ton, a decline of 0.61%. The total inventory of steel has increased by 1.70% to 12.7851 million tons [8][12]. - Apparent consumption of five major steel products was 8.0174 million tons, down 0.96% week-on-week but up 28.96% year-on-year [21]. - The production of five major steel products was 8.2317 million tons, an increase of 0.44% week-on-week [12][37]. Supply and Demand Dynamics - Approximately 60% of steel companies are currently operating at a loss, indicating a market-driven supply clearance is beginning to occur [4]. - The construction sector's demand for steel is expected to stabilize, while demand from infrastructure and manufacturing is projected to grow steadily [4]. Profitability and Production Margins - The average gross profit for rebar was 196.9 CNY/ton, down 11.7 CNY/ton from the previous week, while hot-rolled coil profit increased by 2.3 CNY/ton to 46.9 CNY/ton [39]. - The profitability rate of 247 steel companies was 39.39%, a decrease of 1.3% from the previous week [28]. Recommendations - The report recommends focusing on companies with leading technology and product structures, such as Baosteel and Hualing Steel, as well as low-cost firms like Fangda Special Steel and New Steel [4]. - It also highlights the potential of upstream resource companies like Hebei Resources and Erdos, which may benefit from a recovery in demand [4].

股票研究 /[Table_Date] 2026.02.01 持续推荐创新药械产业链 [Table_Industry] 医药 ——国泰海通医药 2026 年 2 月月报 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | 郑琴(分析师) | 021-23219808 | zhengqin@gtht.com | S0880525040108 | | 谈嘉程(分析师) | 021-38038429 | tanjiacheng@gtht.com | S0880523070004 | 本报告导读： 持续推荐创新药械及产业链。 投资要点： | [Table_Invest] | | | --- | --- | | 评级： | 增持 | [Table_Report] 相关报告 医药《V940 五年随访数据披露，mRNA 肿瘤疫 苗长期价值验证》2026.01.30 医药《支持政策不断，持续推荐创新药械产业 链》202 ...

股票研究 /[Table_Date] 2026.02.01 持续推荐创新药械产业链 [Table_Industry] 医药 ——国泰海通医药 2026 年 2 月月报 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | 郑琴(分析师) | 021-23219808 | zhengqin@gtht.com | S0880525040108 | | 谈嘉程(分析师) | 021-38038429 | tanjiacheng@gtht.com | S0880523070004 | 本报告导读： 持续推荐创新药械及产业链。 投资要点： | [Table_Invest] | | | --- | --- | | 评级： | 增持 | [Table_Report] 相关报告 医药《V940 五年随访数据披露，mRNA 肿瘤疫 苗长期价值验证》2026.01.30 医药《支持政策不断，持续推荐创新药械产业 链》202 ...